PEAK6’s MoonLake Immunotherapeutics MLTX Stock Holding History

PEAK6’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-5,000	Closed	-$271K	–	3374
2024 Q4	$271K	Buy	+5,000	New	+$255K	﹤0.01%	2433

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

PEAK6's MLTX Position: Q1 2025 in Review

PEAK6 sold out of MoonLake Immunotherapeutics (MLTX) in Q1 2025, closing a stake of 5,000 shares — an estimated $271K sold.

PEAK6 first reported a position in MLTX in Q4 2024 and held it in 1 quarter. The position peaked at $271K in Q4 2024. 136 funds tracked by Wall St. Rank hold MLTX as of Q1 2025.

PEAK6 reported no remaining MoonLake Immunotherapeutics position as of Q1 2025 after selling out during the quarter.
PEAK6 sold 5,000 MoonLake Immunotherapeutics shares in Q1 2025, an estimated $271K.
PEAK6 first reported a position in MoonLake Immunotherapeutics in Q4 2024 and held it in 1 quarter.
PEAK6's MoonLake Immunotherapeutics position peaked at $271K in Q4 2024.
136 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2025.

Based on PEAK6's 13F filing for Q1 2025, filed 14 May 2025.